Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis, is thrilled to announce the preliminary results of its pioneering clinical pharmacokinetic (PK) study, marking a significant milestone in cannabis delivery innovation. The study was conducted through Organigram’s Product Development Collaboration (PDC) and focused on its cutting-edge, patent-pending nanoemulsion technology, trademarked as FAST (Fast Acting Soluble Technology).
The Innovation of FAST Technology
FAST nanoemulsion technology represents a paradigm shift in how cannabis products are formulated and consumed. Unlike conventional cannabis products that can take up to two hours to exhibit effects, FAST aims to offer more rapid onset times and improved bioavailability. This is achieved by reducing the cannabis oil into nano-sized particles, which promotes faster and more efficient absorption into the bloodstream.
The Landmark Clinical Study
The landmark clinical PK study intended to quantify how effectively and quickly cannabinoids from the FAST technology are absorbed and metabolized by the human body. The preliminary results have been promising, showcasing faster onset times and more consistent effects compared to traditional cannabis formulations.
The double-blind, randomized, placebo-controlled study was conducted on a diverse group of participants to ensure statistically significant results. Key endpoints included measuring the time to onset of effects, peak concentration levels, and overall duration of effects. The data gathered serves as a cornerstone for further development and optimization of cannabis-infused products leveraging nanoemulsion technology.
Implications for the Cannabis Industry
The successful completion of this clinical study is a monumental achievement for Organigram and the cannabis industry at large. With the introduction of FAST technology, Organigram is positioning itself at the forefront of cannabis innovation, addressing the industry’s long-standing issues related to product consistency, potency, and consumer satisfaction.
Moreover, the implications of this study extend beyond just recreational use. Faster-acting cannabis formulations could significantly benefit medical cannabis users requiring immediate relief from symptoms such as chronic pain, nausea, and anxiety.
Future Prospects and Commercialization
Organigram is poised to commercialize FAST technology as the first product stemming from its PDC efforts. While the preliminary results are encouraging, the company plans to conduct additional studies to fine-tune the formulations further and expand the range of cannabis products incorporating nanoemulsion technology.
The FAST nanoemulsion technology represents a significant leap forward in cannabis science, said Organigram’s CEO. We are dedicated to leveraging the full potential of this innovation to create superior cannabis experiences for our consumers.
In conclusion, the preliminary results of Organigram’s landmark clinical study on nanoemulsion technology herald a new era in cannabis product offerings. With a faster onset of effects and improved bioavailability, FAST technology is set to redefine consumer expectations and elevate the cannabis experience to unprecedented heights.By showcasing the science and promise behind FAST nanoemulsion technology, Organigram stands positioned to lead the next wave of innovations in the cannabis industry, benefiting both recreational and medical users alike.
Comments